{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:13Z","timestamp":1787008393142,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2202,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1093\/annonc\/mdt368","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T23:55:08Z","timestamp":1378943708000},"page":"2834-2838","source":"Crossref","is-referenced-by-count":78,"title":["Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial"],"prefix":"10.1016","volume":"24","author":[{"given":"E.","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Delarochefordiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Martel-Lafay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Miglianico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Becouarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Juzyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ezra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt368_bb0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"UK Co-ordinating Committee on Cancer Research Lancet. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin","volume":"348","author":"UKCCCR Anal Cancer Trial Working Party","year":"1996","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt368_bb0015","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0020","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0025","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F","article-title":"Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients","volume":"73","author":"Touboul","year":"1994","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt368_bb0030","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1200\/JCO.2008.16.2339","article-title":"Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281)","volume":"26","author":"Meropol","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0035","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0040","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt368_bb0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt368_bb0050","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2010.33.4979","article-title":"Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407","volume":"29","author":"Govindan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0055","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1200\/JCO.2010.31.7875","article-title":"Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA\/B non-small-cell lung cancer: RTOG 0324","volume":"29","author":"Blumenschein","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0060","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2010.31.9715","article-title":"Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB\/II trial (SAKK 75\/06)","volume":"29","author":"Ruhstaller","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0065","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression","volume":"29","author":"Crane","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0070","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/bjc.2012.479","article-title":"EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?","volume":"107","author":"Paliga","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt368_bb0075","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2008.26.15_suppl.4609","article-title":"Phase I study of cetuximab in combination with 5-fluorouraci, cisplatin, and radiotherapy in patients with locally advanced squamous cell anal carcinoma (abstr. #4609)","volume":"26","author":"Olivatto","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1748-717X-7-45","article-title":"IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center","volume":"7","author":"Vieillot","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0085","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2012.30.15_suppl.4030","article-title":"Phase II trials of cetuximab plus cisplatin, 5-fluorouracil and radiation in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal: safety and preliminary efficacy results (abstr. #4030)","volume":"30","author":"Garg","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0090","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2012.30.4_suppl.667","article-title":"Predictive factors of early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy (abstr. #667)","volume":"30","author":"Doyen","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdt368_bb0100","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0105","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt368_bb0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijrobp.2009.11.057","article-title":"Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results","volume":"79","author":"Olivatto","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdt368_bb0115","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0120","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt368_bb0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1023\/A:1008295119573","article-title":"Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study","volume":"8","author":"Peiffert","year":"1997","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/11\/2834\/16701713\/mdt368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:07:58Z","timestamp":1624684078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419373685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0923753419373685"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt368","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}